Company Overview and News

GHDX / Genomic Health, Inc. 8-K (Current Report)


Here's Why You Should Hold Onto Cardinal Health Stock Now

2018-07-23 zacks
With a market capitalization of approximately $15.16 billion, Cardinal Health, Inc’s (CAH - Free Report) Medical and Pharmaceutical offerings lend the company with a competitive edge in the MedTech space. The company offers industry expertise and a solid portfolio of safe medical products like Bathroom Safety, Mobility, and Exam Room Equipment products. However, the company has been facing sluggishness in the exam-gloves unit lately.

Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label

2018-07-20 zacks
Eli Lilly and Company (LLY - Free Report) announced that it has updated its diabetes drug Trulicity’s label to include data from a new study, which showed that the GLP-1 receptor agonist was effective in type II diabetes patients with moderate to severe chronic kidney disease (CKD).

Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

2018-07-20 zacks
Abbott (ABT - Free Report) has been gaining investors’ confidence on consistently positive results. Over the past six months, the company’s share price has outperformed its industry. The stock has gained 7.1%, compared to the industry’s 5.3%. The company has also fared better than the 0.3% decline of the S&P 500 market.

Can the Rally in Genomic Health (GHDX) Shares Continue?

2018-07-20 zacks - 1
Genomic Health, Inc. (GHDX - Free Report) has been on the move lately as the stock has risen by 13.5% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be on investors’ minds right now is; can this trend continue?

AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 11.8% in Session

2018-07-20 zacks - 3
AVEO Pharmaceuticals, Inc. (AVEO - Free Report) was a big mover last session, as the company saw its shares rise more than 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, trading within a volatile range of $1.95-$2.90 in the past one-month time frame, showed a sharp increase yesterday. The move came after the company issued statement on its revised guidance regarding the timing of top-line data from the TIVO-3 study.

Intuitive Surgical (ISRG) Beats on Q2 Earnings & Revenues

2018-07-20 zacks
Intuitive Surgical, Inc (ISRG - Free Report) reported adjusted earnings of $2.76 per share in the second quarter of 2018, which beat the Zacks Consensus Estimate of $2.48. Adjusted Earnings improved 38% year over year.

Neogen (NEOG) Earnings and Revenues Beat Estimates in Q4

2018-07-19 zacks
Neogen Corporation (NEOG - Free Report) reported earnings of 33 cents per share in the fourth quarter of fiscal 2018. The figure considersadjustment for a 4-for-3 stock split effective Dec 29, 2017.The bottom line beat the Zacks Consensus Estimate by 33.3% and increased 10% from the year-ago quarter’s tally.

Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings?

2018-07-19 zacks
Align Technology, Inc.’s (ALGN - Free Report) solid Invisalign Technology prospects and growth in North America and internationally, particularly in the Asia-Pacific and EMEA regions, raise optimism. The continued strong uptake of iTero scanners across all geographies is impressive.

Abbott (ABT) Q2 Earnings & Revenues Top Estimates, View Up

2018-07-18 zacks
Abbott Laboratories (ABT - Free Report) reported second-quarter 2018 adjusted earnings from continuing operations of 73 cents per share, beating the Zacks Consensus Estimate by a couple of cents. The bottom line also improved 17.7% year over year and exceeded the company’s guided range of 70-72 cents. Moreover, reported earnings from continuing operation in the quarter came in at 40 cents per share compared with the year-ago figure of 15 cents.

Haemonetics Gains on Strong Plasma, Wider Global Footprint

2018-07-17 zacks
On Jul 16, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) . The company has been benefiting from a steady momentum in new business generation and geographical expansion. The stock carries a Zacks Rank #2 (Buy).

Is Genomic Health (GHDX) Stock Outpacing Its Medical Peers This Year?

2018-07-17 zacks
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Genomic Health (GHDX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of GHDX and the rest of the Medical group's stocks.

Is Genomic Health (GHDX) Stock Outpacing Its Medical Peers This Year?

2018-07-17 zacks
Investors focused on the Medical space have likely heard of Genomic Health (GHDX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of GHDX and the rest of the Medical group's stocks.

Here's Why You Should Hold Onto Opko Health (OPK) Stock Now

2018-07-17 zacks - 2
With a market capitalization of approximately $3.28 billion, Opko Health, Inc. (OPK - Free Report) has been riding high on solid prospects in RAYLDEE and BioReference platforms. The company’s consistent focus in R&D bodes well. However, the company faces cutthroat competition in the niche space. The company has been incurring operating losses due to limited revenues from the pharmaceutical operations and sale of the 4Kscore test.

AngioDynamics (ANGO) Q4 Performance Dull, Competition Rife

2018-07-17 zacks
On Jul 16, we issued an updated research report on AngioDynamics (ANGO - Free Report) . It is currently one of the underperforming stocks in the MedTech space. A soft fiscal fourth-quarter performance and high debt levels raise concern.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to GHDX / Genomic Health, Inc. on message board site Silicon Investor.

Genomic Health: predicting the course of an individualu0027s can Genomic Health: predicting the course of an individualu0027s can Genomic Health: predicting the course of an individualu0027s can
CUSIP: 37244C101